Artemis Medicare Services Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of Rs. 0.45 per equity share.
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Artemis Medicare Services reported strong FY25 standalone results with revenue from operations rising about 8% to Rs. 913.26 crore (from Rs. 845.23 crore) and net profit jumping roughly 70% to Rs. 83.46 crore (from Rs. 49.15 crore). EBITDA margin expanded from about 16% to 20% YoY, driving most of the profit growth. For Q4 FY25, revenue grew about 8% to Rs. 234.80 crore while net profit surged about 67% to Rs. 23.20 crore. The Board recommended a final dividend of Rs. 0.45 per equity share (45% on the Re. 1 face value), subject to shareholder approval. Auditor T R Chadha & Co LLP issued an unmodified (clean) opinion on both standalone and consolidated results. Other decisions included the appointment of Mr. Sunam Sarkar as a Non-Executive Director, the resignation of Dr. Nirmal Kumar Ganguly, the exit of Ms. Deepa Gopalan Wadhwa on completion of her independent director term, and the appointment of DMK Associates as secretarial auditor for five years (FY26–FY30). The company had also raised Rs. 330 crore via Compulsorily Convertible Debentures to IFC, which is reflected in sharply higher bank balances.
The strong profit growth and EBITDA margin expansion are positive signals for shareholders, and the 45% dividend reflects healthy cash generation. The balance sheet is much stronger post the IFC CCD infusion, though conversion of those CCDs into equity could lead to future dilution. The board turnover is routine and unlikely to materially affect operations.